Skip to main content

Table 1 Application of upper gastrointestinal tract complications (UGIC) risk estimations to the populations of patients included in the control groups (exposed to traditional non-steroidal anti-inflammatory drugs) for the Vioxx Gastrointestinal Outcomes Research (VIGOR), Celecoxib Long-term Arthritis Safety Study (CLASS), and Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) trials

From: Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications

Study Age mean Female % Ulcer History % Aspirin % Reported Incidence Per 1,000 p-y Estimated Incidence Per 1,000 p-y
VIGOR [21] 58 80 7.8 0 8.6* 7.0
CLASS [22] 60 69 9.6 20 14.5 9.5
TARGET [23] 63 76 3.5 24 9.1 8.1
  1. *Excluding 11 cases with gastrointestinal ulcer without apparent bleeding, obstruction, or perforation.